Institute of Clinical Research, Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, PR China.
Department of Physiology, Institute of Neuroscience Research, Hengyang Key Laboratory of Neurodegeneration and Cognitive Impairment, Hengyang Medical School, University of South China, Hengyang, Hunan, PR China.
J Cardiovasc Pharmacol. 2022 Apr 1;79(4):444-455. doi: 10.1097/FJC.0000000000001208.
The abnormal proliferation of vascular smooth muscle cells (VSMCs) is a key pathological characteristic of vascular proliferative diseases. Mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine kinase that plays an important role in regulating cell growth, motility, proliferation, and survival, as well as gene expression in response to hypoxia, growth factors, and nutrients. Increasing evidence shows that mTOR also regulates VSMC proliferation in vascular proliferative diseases and that mTOR inhibitors, such as rapamycin, effectively restrain VSMC proliferation. However, the molecular mechanisms linking mTOR to vascular proliferative diseases remain elusive. In our review, we summarize the key roles of the mTOR and the recent discoveries in vascular proliferative diseases, focusing on the therapeutic potential of mTOR inhibitors to target the mTOR signaling pathway for the treatment of vascular proliferative diseases. In this study, we discuss mTOR inhibitors as promising candidates to prevent VSMC-associated vascular proliferative diseases.
血管平滑肌细胞（VSMCs）的异常增殖是血管增殖性疾病的一个关键病理特征。哺乳动物雷帕霉素靶蛋白（mTOR）是一种进化上保守的丝氨酸/苏氨酸激酶，在调节细胞生长、运动、增殖和存活以及基因表达方面发挥着重要作用，以响应缺氧、生长因子和营养物质。越来越多的证据表明，mTOR 也调节血管增殖性疾病中的 VSMC 增殖，并且 mTOR 抑制剂，如雷帕霉素，有效地抑制 VSMC 增殖。然而，mTOR 与血管增殖性疾病之间的分子机制仍不清楚。在我们的综述中，我们总结了 mTOR 的关键作用以及在血管增殖性疾病中的最新发现，重点讨论了 mTOR 抑制剂作为靶向 mTOR 信号通路治疗血管增殖性疾病的治疗潜力。在这项研究中，我们讨论了 mTOR 抑制剂作为预防与 VSMC 相关的血管增殖性疾病的有前途的候选药物。
